ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Corbus Pharmaceuticals Holdings (CRBP) pipeline and stated timing

Name in SEC filings: Corbus Pharmaceuticals Holdings, Inc.

Pipeline at a glance

ProgramEventStageStated timingFiling
CRB-913/data readoutPhase 1November 14 – 17, 20268-K ·
CRB-701 + pembrolizumabTopline/data readoutStage not stated 20278-K ·

Source: ORION, orionbiotechai.com/company/CRBP, data as of Oct 13, 2026
https://www.orionbiotechai.com/company/CRBP

Nearest upcoming stated timing: CRB-913 · Topline/data readout · November 14 – 17, 2026

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
CRB-701 + pembrolizumabClinical resultsQ1 2027
“CRB-701 + pembrolizumab data in 1L OPSCC in Q1 2027”

Filed · EX-99.2

Period not started

The stated period has not started yet, so there is nothing to compare.

CRB-913Clinical resultsNovember 14 – 17, 2026
“will be detailed in a late-breaking presentation at ObesityWeek® 2026, to be held November 14 – 17, 2026.”

Filed · EX-99.1

Period not started

The stated period has not started yet, so there is nothing to compare.

CRB-701 + pembrolizumabClinical resultsearly 2027
“anticipated data readout of CRB-701 in 1L OPSCC in early 2027”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

CRB-701 + pembrolizumabClinical resultsQ4 2026
“HNSCC patients in Q4 2026.”

Filed · EX-99.1

Not compared

ORION has no confirmed start and end dates for this wording, so it is not compared with filings.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Retained founder-checked records

These dated records retain their original scope and check dates.

CRB-701 + pembrolizumab / first-line OPSCC · 1L combination clinical data

Record A20-CRBP-701-1L-COMBO · Clinical results disclosure · Window open

Last checked: .

First stated window
“Q1 2027”SEC Exhibit 99.1, filed
Disclosure date
None foundLast checked:

Initial statement

· Checked by founder · SEC Exhibit 99.1

Stated period: Q1 2027

Anticipate reporting CRB-701 + Keytruda® combination data in first-line (1L) settings in OPSCC patients in Q1 2027

Statement retained

· Checked by founder · Company press release

Stated period: Q1 2027

Anticipate reporting CRB-701 + Keytruda® combination data in first-line (1L) settings in OPSCC patients in Q1 2027

Statement retained

· Checked by founder · SEC Exhibit 99.2

Stated period: Q1 2027

Report CRB-701 + pembrolizumab data in 1L — Q1 2027

Sources and scope

Company release: · Company original

Company release: · Company original

Company press release listing · checked

The initial entry means the earliest wording located within the sources checked; an exhaustive history is not asserted.

Company timing wording is retained. A newer corporate release about another program does not establish a results announcement for this trial.

SEC filings searched through : and Ex-99.1 Jan–Aug 2026, Mar 31, Ex-99.2 Sep 2026 checked for CRB-701 1L combination timing.

Company press releases checked : Press releases page checked on Oct 10; CRB-913 obesity items are a separate program.

Checked by founder: .

Corrections

Corbus Pharmaceuticals (CRBP) — CRB-701 + pembrolizumab / first-line OPSCC · 1L combination clinical data: “Q1 2027” (SEC Exhibit 99.1 2026-08-06); statement retained “Q1 2027” (2026-08-06); statement retained “Q1 2027” (2026-09-14). Status Window open, checked 2026-10-10. Sources: https://www.sec.gov/Archives/edgar/data/1595097/000119312526336864/crbp-ex99_1.htm | https://ir.corbuspharma.com/news-events/press-releases/detail/475/corbus-pharmaceuticals-reports-q2-2026-financial-results-and-provides-a-corporate-update | https://ir.corbuspharma.com/sec-filings/all-sec-filings/content/0001193125-26-389829/crbp-ex99_2.htm

Retained program pages

Watch CRBP

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for CRBP. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See CRBP in the calendar · Review labels and methodology

Topline results are the main summary results of a clinical trial, released before the full data.Q1–Q4 (also written 1Q–4Q) are quarters of the year: Q1 is January–March, Q2 April–June, Q3 July–September and Q4 October–December, unless the company uses a different fiscal year.A Form 8-K is a report a company files with the SEC to announce a significant event between its regular reports.A Form 10-Q is a company’s quarterly report to the SEC, with unaudited financial statements.